RxDoctor Payments DataLook up a doctor →

Rakesh Shah, MD

Cardiovascular Disease · Langhorne, PANPI 1144297219

Payments from drug & device makers

$256,426in general payments, 2019–2025

Across 625 payments — averaging $410.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$109K
  • Boston Scientific$51K
  • AstraZeneca$41K
  • Eisai Inc.$29K
  • Esperion Therapeutics, Inc.$17K
  • Impulse Dynamics (USA) Inc.$1K
  • plus $7K from 40 others

What the payments were for

  • Speaking & faculty fees$193,37588%
  • Travel & lodging$10,5545%
  • Food & beverage$16,6178%
  • Education$610%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$256,426 in reported general payments places this provider in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$275,069
Medicare patients
1,181
Services billed
2,937

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis17$672,407
EliquisApixaban281$371,397
FarxigaDapagliflozin Propanediol177$201,560
XareltoRivaroxaban88$112,802
Repatha SureclickEvolocumab86$67,734
EntrestoSacubitril/Valsartan41$56,055
JardianceEmpagliflozin52$50,056
BrilintaTicagrelor53$46,800
Valsartan538$28,741
Praluent PenAlirocumab24$26,350
Ezetimibe576$19,122
Icosapent Ethyl37$16,082
Atorvastatin Calcium916$16,077
VascepaIcosapent Ethyl15$14,914
OzempicSemaglutide11$13,750

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$634$1,043,804298 claims
AstraZenecaFarxiga, Brilinta$41,109$248,360230 claims
Johnson & JohnsonXarelto$1,142$112,80288 claims
NovartisEntresto$803$56,05541 claims
Novo NordiskOzempic$109,269$13,75011 claims
Esperion Therapeutics, Inc.Nexlizet$17,150$10,27217 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Langhorne

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →